Conexeu Sciences Expands Board with Three Pharma Veterans, Elevates Co-Founder to CCO
SYK•Conexeu Sciences expanded its board from six to nine, appointing three directors with senior roles at Kyowa Kirin, Lucid Hearing, and RX3 Growth Partners. Co-founder David Bogart was promoted to Chief Commercial Officer and Melinda Farina joined the advisory board to support the company's aesthetics commercialization push.
1. Board Expansion and New Directors
Conexeu expanded its board from six to nine directors by appointing Ana Bastiani-Posner as Compensation Committee chair and Audit Committee member, April Burke to both committees, and Andrew Costa as Audit Committee chair, drawing on expertise from Kyowa Kirin, Lucid Hearing, RX3 Growth Partners, Morgan Stanley, and J.P. Morgan.
2. Co-Founder Promoted to Chief Commercial Officer
Co-founder and director David Bogart was elevated to Chief Commercial Officer to lead commercial strategy and operations, leveraging his role in shaping the platform’s IP, regulatory pathway, and advising on more than $75 million in capital formation since the company’s inception.
3. Aesthetics Advisor Appointment
Melinda Farina, known as the Beauty Broker and founder of Integrated Aesthetics Consulting, joined the advisory board, bringing nearly 30 years of consumer-health, brand-development, and market-positioning expertise to advance Conexeu’s aesthetics market ambitions.
4. Strategic Implications and Commercial Pathway
These governance moves underscore Conexeu’s push to establish financial and operational discipline ahead of a targeted early-2027 FDA 510(k) submission for its preclinical CXU™ extracellular matrix platform, signaling a shift from scientific development toward scalable commercialization.
